“Underpowered” Cancer Trials Are Becoming “Major Problem” – FDA’s Pazdur
Executive Summary
Cancer drug trials that are statistically "underpowered" because of their small size are becoming a "major problem," FDA Oncologic Drug Products Division Director Richard Pazdur, MD, told a joint American Society of Clinical Oncology/FDA workshop April 15 in Alexandria, Va
You may also be interested in...
FDA’s NSCLC Guidance Stresses Overall Survival Endpoint, Sets PFS Standards
FDA is using its new draft guidance on non-small cell lung cancer to once again stress the importance of using overall survival to prove efficacy and make clear that if progression-free survival measure is used, a “substantial and robust” effect should be shown.
FDA’s NSCLC Guidance Stresses Overall Survival Endpoint, Sets PFS Standards
FDA is using its new draft guidance on non-small cell lung cancer to once again stress the importance of using overall survival to prove efficacy and make clear that if progression-free survival measure is used, a “substantial and robust” effect should be shown.
Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says
An endpoint of progression-free survival is appropriate for full approval of first-line non-small cell lung cancer treatments in metastatic cancers, but not for earlier-stage disease, the Oncologic Drugs Advisory Committee concluded Dec. 16